E3 ubiquitin ligase NKLAM/RNF19b suppresses myc-driven B cell lymphomagenesis in Eμ-myc mice - Takeaways - MDSpire

E3 ubiquitin ligase NKLAM/RNF19b suppresses myc-driven B cell lymphomagenesis in Eμ-myc mice

  • By

  • Richard G. Hoover

  • Emily C. Matchett

  • Jacki Kornbluth

  • July 15, 2026

Share

  • 1

    NKLAM, also known as RNF19b, is an E3 ubiquitin ligase that plays a role in regulating tumor development in vivo.

  • 2

    NKLAM deficiency in Eμ-myc mice leads to accelerated development of B cell lymphomas compared to wild type mice.

  • 3

    NKLAM KO Eμ-myc mice exhibit higher levels of precursor B cells that express more myc and Bcl-2, persisting longer than in WT mice.

  • 4

    Infusion of NKLAM+ immune cells into NKLAM-deficient Eμ-myc mice extends survival and promotes development of less immunogenic lymphomas.

  • 5

    NKLAM contributes to both early and late phases of myc-driven B cell lymphomagenesis by limiting myc and Bcl-2 expression.

Original Source(s)

E3 ubiquitin ligase NKLAM/RNF19b suppresses myc-driven B cell lymphomagenesis in Eμ-myc mice

  • by Richard G. Hoover, Emily C. Matchett, Jacki Kornbluth

  • July 15, 2026

Related Content

Predictive modeling for survival-related outcomes in lung cancer patients with brain metastases: a mini-review

Galectins at the crossroads of tumor immunity, metabolism, and metastasis: mechanisms, therapeutic resistance, and translational opportunities

First-line penpulimab combined with anlotinib achieves complete response in an elderly patient with occult lung squamous cell carcinoma: a case report